Zidovudine (3’-azido-3’-deoxythymidine, AZT), administered to pregnant women alone or in combination with other antiretroviral drugs, greatly reduces the mother-to-child transmission of HIV-1. The potential genotoxicity of these molecules is underestimated and wide-ranging evaluation of its biological and clinical consequences is required.
Methods
We investigated the nuclear organization of constitutive heterochromatin, a major domain participating in epigenetic regulation, in uninfected infants born to HIV-1-infected mothers treated with zidovudine and/or other nucleoside reverse transcriptase inhibitors (NRTIs) during pregnancy. We studied the organization of chromosome 1 heterochromatin (1q12) in peripheral leukocytes of 25 HIV-1-uninfected children (newborn to 9 years old): children born to HIV-1-infected mothers exposed to zidovudine and/or other NRTIs (n=15), children born to HIV-1-infected mothers not exposed to any NRTIs (n=6) and children born to HIV-1-uninfected mothers (n=4).
Results
Results differed significantly between NRTI-exposed and -unexposed children. By contrast, there was no difference between NRTI-unexposed children born to HIV-1-infected mothers and children born to HIV-uninfected mothers. The anomaly persisted in lymphocytes cultured for 48 h. There was no evidence of abnormal DNA methylation, a major feature of constitutive heterochromatin and associated with the loss of its structure. In a complementary sample of children, analysis of chromosome 11 and 16 heterochromatin suggests that the defect affects most of the other heterochromatic sites of the human genome. The heterochromatin defect persists long after the end of the exposure and appears in leukocytes of both myeloid and lymphoid lineages, suggesting that haematopoietic stem cells are affected.
References
1.
ConnorE.M., SperlingR.S., GelberR.Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.N Engl J Med1994; 331: 1173–1180.
2.
ScotlandG.S., van TeijlingenE.R., van der PolM., SmithW.C.A review of studies assessing the costs and consequences of interventions to reduce mother-to-child HIV transmission in sub-Saharan Africa.AIDS2003; 17: 1045–1052.
3.
FurmanP.A., FyfeJ.A., St ClairM.H.Phosphorylation of 3’-azido-3’-deoxythymidine and selective interaction of the 5’-triphosphate with human immunodeficiency virus reverse transcriptase.Proc Natl Acad Sci U S A1986; 83: 8333–8337.
4.
Vazquez-PaduaM.A., StarnesM.C., ChengY.C.Incorporation of 3’-azido-3’-deoxythymidine into cellular DNA and its removal in a human leukemic cell line.Cancer Commun1990; 2: 55–62.
5.
LewisW.Mitochondrial dysfunction and nucleoside reverse transcriptase inhibitor therapy: experimental clarifications and persistent clinical questions.Antivir Res2003; 58: 189–197.
6.
WutzlerP., ThustR.Genetic risks of antiviral nucleoside analogues - a survey.Antivir Res2001; 49: 55–74.
7.
OliveroO.A., AndersonL.M., DiwanB.A.Transplacental effects of 3’-azido-2’,3’-dideoxythymidine (AZT): tumorigenicity in mice and genotoxicity in mice and monkeys.J Natl Cancer Inst1997; 89: 1602–1608.
8.
OliveroO.A., ShearerG.M., ChougnetC.A.Incorporation of zidovudine into leukocyte DNA from HIV-1-positive adults and pregnant women, and cord blood from infants exposed in utero.AIDS1999; 13: 919–925.
9.
GerschensonM., NguyenV., EwingsE.L.Mitochondrial toxicity in fetal Erythrocebus patas monkeys exposed transplacentally to zidovudine plus lamivudine.AIDS Res Hum Retroviruses2004; 20: 91–100.
10.
WalkerD.M., PoirierM.C., CampenM.J.Persistence of mitochondrial toxicity in hearts of female B6C3F1 mice exposed in utero to 3’-azido-3’-deoxythymidine.Cardiovasc Toxicol2004; 4: 133–153.
11.
BlancheS., TardieuM., RustinP.Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues.Lancet1999; 354: 1084–1089.
12.
CooperE., DiMauroS., SullivanM.Biopsy-confirmed mitochondrial dysfunction in an HIV-exposed infant whose mother received combination antiretrovirals during the last 6 weeks of pregnancy. XV International AIDS Conference. 11–16 July 2004, Bangkok, Thailand. Abstract TuPeB4394.
13.
OliveroO.A., FernandezJ.J., AntiochosB.B.Transplacental genotoxicity of combined antiretroviral nucleoside analogue therapy in Erythrocebus patas monkeys.J Acquir Immune Defic Syndr2002; 29: 323–329.
14.
PoirierM.C., DiviR.L., Al-HarthiL.Long-term mitochondrial toxicity in HIV-uninfected infants born to HIV-infected mothers.J Acquir Immune Defic Syndr2003; 33: 175–183.
15.
AyersK.M., TorreyC.E., ReynoldsD.J.A transplacental carcinogenicity bioassay in CD-1 mice with zidovudine.Fundam Appl Toxicol1997; 38: 195–198.
16.
DiwanB.A., RiggsC.W., LogsdonD.Multiorgan transplacental and neonatal carcinogenicity of 3’-azido-3’-deoxythymidine in mice.Toxicol Appl Pharmacol1999; 161: 82–99.
17.
National Toxicology Program. Technical Report on the Toxicology and carcinogenesis studies of transplacental AZT (CAS No. 30516-87-1) in Swiss (CD–1) mice (in utero studies). NTP TR 522, NIH Publication No. 06-4458, 2006.
18.
HansonI.C., AntonelliT.A., SperlingR.S.Lack of tumors in infants with perinatal HIV-1 exposure and fetal/neonatal exposure to zidovudine.J Acquir Immune Defic Syndr Hum Retrovirol1999; 20: 463–467.
19.
BroglyS., WilliamsP., SeageG.R.3rd, Van DykeR.In utero nucleoside reverse transcriptase inhibitor exposure and cancer in HIV-uninfected children: an update from the pediatric AIDS clinical trials group 219 and 219C cohorts.J Acquir Immune Defic Syndr2006; 41: 535–536.
20.
ParraI., FloresC., AdrianD., WindleB.AZT induces high frequency, rapid amplification of centromeric DNA.Cytogenet Cell Genet1997; 76: 128–133.
21.
RichardsE.J., ElginS.C.Epigenetic codes for heterochromatin formation and silencing: rounding up the usual suspects.Cell2002; 108: 489–500.
22.
GrewalS.I., MoazedD.Heterochromatin and epigenetic control of gene expression.Science2003; 301: 798–802.
23.
BombailV., MoggsJ.G., OrphanidesG.Perturbation of epigenetic status by toxicants.Toxicol Lett2004; 149: 51–58.
24.
MoggsJ.G., GoodmanJ.I., TroskoJ.E., RobertsR.A.Epigenetics and cancer: implications for drug discovery and safety assessment.Toxicol Appl Pharmacol2004; 196: 422–430.
25.
MoorheadP.S., NowellP.C., MellmanW.J.Chromosome preparations of leukocytes cultured from human peripheral blood.Exp Cell Res1960; 20: 613–616.
26.
JiangY.L., RigoletM., Bourc'hisD.DNMT3B mutations and DNA methylation defect define two types of ICF syndrome.Hum Mutat2005; 25: 56–63.
27.
IsogaiY., TjianR.Targeting genes and transcription factors to segregated nuclear compartments.Curr Opin Cell Biol2003; 15: 296–303.
28.
McNairnA.J., GilbertD.M.Epigenomic replication: linking epigenetics to DNA replication.Bioessays2003; 25: 647–656.
29.
AdamsR.R., WheatleyS.P., GouldsworthyA.M.INCENP binds the Aurora-related kinase AIRK2 and is required to target it to chromosomes, the central spindle and cleavage furrow.Curr Biol2000; 10: 1075–1078.
30.
CsinkA.K., HenikoffS.Something from nothing: the evolution and utility of satellite repeats.Trends Genet1998; 14: 200–204.
31.
XuG.L., BestorT.H., Bourc'hisD.Chromosome instability and immunodeficiency syndrome caused by mutations in a DNA methyltransferase gene.Nature1999; 402: 187–191.
32.
NarayanA., JiW., ZhangX.Y.Hypomethylation of pericentromeric DNA in breast adenocarcinomas.Int J Cancer1998; 77: 833–838.
33.
JuttermannR., LiE., JaenischR.Toxicity of 5-aza-2’-deoxy-cytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation.Proc Natl Acad Sci U S A1994; 91: 11797–11801.
34.
GhoshalK., DattaJ., MajumderS.5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal.Mol Cell Biol2005; 25: 4727–4741.
35.
JonesP.A., BaylinS.B.The fundamental role of epigenetic events in cancer.Nat Rev Genet2002; 3: 415–428.
36.
EggerG., LiangG., AparicioA., JonesP.A.Epigenetics in human disease and prospects for epigenetic therapy.Nature2004; 429: 457–463.
37.
Blanco-BetancourtC.E., MonclaA., MililiM.Defective B-cell-negative selection and terminal differentiation in the ICF syndrome.Blood2004; 103: 2683–2690.
38.
Le ChenadecJ., MayauxM.J., Guihenneuc-JouyauxC., BlancheS.Perinatal antiretroviral treatment and hematopoiesis in HIV-uninfected infants.AIDS2003; 17: 2053–2061.
39.
European Collaborative Study.Levels and patterns of neutrophil cell counts over the first 8 years of life in children of HIV-1-infected mothers.AIDS2004; 18: 2009–2017.
40.
SmaleS.T.The establishment and maintenance of lymphocyte identity through gene silencing.Nat Immunol2003; 4: 607–615.
41.
AlcobiaI., DilaoR., ParreiraL.Spatial associations of centromeres in the nuclei of hematopoietic cells: evidence for cell-type-specific organizational patterns.Blood2000; 95: 1608–1615.
42.
AlcobiaI., QuinaA.S., NevesH., ClodeN., ParreiraL.The spatial organization of centromeric heterochromatin during normal human lymphopoiesis: evidence for ontogenically determined spatial patterns.Exp Cell Res2003; 290: 358–369.
43.
BrownK.E., BaxterJ., GrafD., MerkenschlagerM., FisherA.G.Dynamic repositioning of genes in the nucleus of lymphocytes preparing for cell division.Mol Cell1999; 3: 207–217.
